PNC
DGX icon

Park National Corp’s Quest Diagnostics DGX Stock Holding History

Park National Corp’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.6K Sell
399
-80
-17% -$15.7K ﹤0.01% 331
2026
Q1 		$93.9K Buy
+479
New +$93.1K ﹤0.01% 329

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Park National Corp's DGX Position: Q2 2026 in Review

Park National Corp reduced its Quest Diagnostics (DGX) stake by 17% in Q2 2026, selling an estimated $15.7K and leaving 399 shares worth $84.6K. The position accounts for ﹤0.01% of the portfolio, ranked #331.

Park National Corp first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $93.9K in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Park National Corp held 399 shares of Quest Diagnostics worth $84.6K as of Q2 2026.
  • Park National Corp sold 80 Quest Diagnostics shares in Q2 2026, an estimated $15.7K.
  • Quest Diagnostics made up ﹤0.01% of Park National Corp's portfolio in Q2 2026, its #331 holding.
  • Park National Corp first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • Park National Corp's Quest Diagnostics position peaked at $93.9K in Q1 2026.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Park National Corp's 13F filing for Q2 2026, filed 15 Jul 2026.